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134 Poster Presentation Abstractsthan the control. We further confirmed that the IL-6 level was significantly
increased by KGN in both cytoplasm and supernatant media of CPC culture.
We further demonstrated that the phosphosphorylation of Stat-3 was up-
regulated at the same time. In-articular injection of KGN were also found to
increase the number of BrdU-labeled slow-cycling cells. In vivo experimental
evidences of the increased thickness in articular cartilage with KGN treatment
was further confirmed in the rat model that were induced to have knee joint
injury. IHC staining of the KGN treatment group showed up-regulate of Stat-3
phosphosphorylation in KGN-treated cartilage.
Discussion and Conclusions: Based on the in vivo and in vitro data, we propose
that KGN may improve the number of endogenous cartilage stem cells by promot-
ing their self-renewal in situ while inducing chondrogenesis and its use in cartilage
regeneration and repair is definitely worth of further explored.
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Sox9 SUPPRESSES THE HYPERTROPHY OF CHONDROCYTES BY INHIBITING
wnt/b-CATENIN SIGNALING PATHWAY
Kun Chen, Peng Cheng, Min Zhou, Yuting Wang, Anmin Chen
Tongji Hospital, Tongii Medical College, Huazhong University of Science and
Technology, China
Background: Due to its low cell density and low proliferative activity, and its avas-
cular character, articular cartilage is virtually unable to regenerate or self-heal
upon injury or degeneration by common diseases such as osteoarthritis. Scientists
have tried many ways to inhibit the degeneration of chondrocytes or repair the
cartilage defect. However, there is still no effective solutions to these problems.
Sox9 has been reported as an important transcription factor during the develop-
ment of cartilage. We have thought to overexpress Sox9 to see its role in
chondrocytes.
Subjects and Methods: The lentivirus vector was constructed to overexpress the
Sox9 in the chondrocytes. And the plasmids contain the full Sox9 and DC, DN
Sxo9 were constructed. These lentivirus and plasmids were transfected to the
articular chondrocytes of SD rats. Then western-blot, immunofluorescence, and
Alician blue staining were done to test the change of chondrocytes in order to
find the role of Sox9 in the chondrocytes.
Results: When chondrocytes were transfected with lentivirus to overexpress Sox9,
Western-blot showed that the expression of COL2a was upregulated and the
expression of COL10 and RUNX2 was downregulated. Meanwhile, the b-catenin
and p-GSK-3b were downregulated and the p-b-catenin and GSK-3b were upregu-
lated. And these changes can be relieved when Gsk inhibitor Licl and SB were
used. The Alician blue staining showed that when used wnt/b-catenin activator
Wnt3A to treat chondrocytes was weaker than the control group and the Sox9 over-
expression group was stronger than the control group. These results indicate that
the overexpression of Sox9 in chondrocytes can suppress the expression of RUNX2
and COL10 in chondrocytes and suppress the hypertrophy of chondrocytes. And
Sox9 acts through inhibiting wnt/b-catenin signaling pathway by activating the
GSK–3b. Furthermore, when chondrocytes were transfected with plasmids of
Sox9, DC and DN Sxo9, the Western-blot showed that in Sox9, DC Sox9 and DN
Sxo9 groups, b-catenin COL10 and RUNX2 were downregulated, while p-b-catenin,
GSK-3b and COL2a were upregulated. And the DC group was changed more signif-
icantly than the DN Sox9 group. These results suggest that the DC part of Sox9 may
play the main role in the function of Sox9 in chondrocytes.
Discussion and Conclusion: According to the results, Sox9 can suppress the hyper-
trophy of chondrocytes. And it acts through inhibiting the phosphorylation of GSK-
3b, and then inhibit the wnt/b-catenin signaling pathway. This makes Sox9 a prom-
ising way to treat the hypertrophy of chondrocytes.
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STUDY ON THE EFFECT OF PKC-z IN SDF-1a/CXCR4 AXIS INDUCED MIGRATION
OF RAT BONE MARROW MESENCHYMAL STEM CELLS
Hui Liu, Yonghui Dong, Peng Cheng, Kun Chen, Anmin Chen, Hui Huang
Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Technology, China
Background: Bone mesenchymal stem cells (BMSCs) are bone marrow-derived cells
with multipotent differentiation capability that can differentiate into osteoblasts,
adipocytes and chondrocytes. BMSCs have generated a lot of interest because oftheir potential use in regenerative medicine and tissue engineering. A great deal
of studies have shown that the SDF-1a is critical for mesenchymal stem cells migra-
tion to injured tissue through interaction with its cognate CXCR4 on the surface of
these cells. However, migration signaling pathways required for homing and
recruitment of BMSCs are not fully understood. Due to the known effects of
PKC-z on the migration of cancers and CD34+ progenitor cells, we have sought to
investigate the relationship between PKC-z and SDF-1a/CXCR4 axis induced migra-
tion of BMSCs.
Subjects and Methods: The rat BMSCs were cultured by using the whole bone
marrow adherence method. The three-line differentiations of BMSCs was conduct-
ed and cell surface markers were identified by flow cytometry. Transwell migration
assay was used to observe the migrating number of BMSCs that were treated with
AMD3100 and PS-z in response to SDF-1a. Western blot analysis was used to analyze
the phosphorylation of PKC-z of BMSCs upon SDF-1a and PS-z stimulation. Actin-
Tracker Green was applied to illustrate morphology of cell cytoskeleton by staining
of the F-actin. Laser scanning confocal microscopy was used to observe the polar-
ization of BMSCs after SDF-1a stimulation.
Results: The BMSCs that were cultured in vitro had the potential of multiple differ-
entiation into osteoblasts or adipocytes and highly expressed CD29 and CD90
except CD45.The migrating number of BMSCs increased gradually with the increase
of SDF-1a concentration in vitro, and the amount of BMSCs in the filter membrane
was approximately maximum when SDF-1a was 100ng/mL, but AMD3100 and PS-z
were able to cut down the number of BMSCs in the filter membrane. SDF-1a
increased the level of phosphorylation of PKC-z, while PS-z inhibited the phosphor-
ylation of PKC-z. Laser confocal microscopy confirmed that the cytoskeleton of
BMSCs treated with SDF-1a changes significantly, but AMD3100 and PS-z inhibited
this effects.
Discussion and Conclusion: Our result suggests that SDF-1a induces the migration
of BMSCs via affecting the phosphorylation of signaling protein PKC-z and changing
the cytoskeleton of BMSCs. This may increase the number of transplanted BMSCs
migration to injured tissue and organ to promote the rehabilitation.
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Notch1-ANTAGONISTIC APTAMER FOR CHONDROGENIC DIFFERENTIATION OF
BONE MARROW STROMAL CELLS
Se-Young Jeong, Mi-Lan Kang, Ji-Eun Kim, Gun-Il Im
Dongguk University Ilsan Hospital, South Korea
Introduction: Aptamers are oligonucleotide or peptide molecules that bind to a
specific target molecule such as small molecules, proteins, nucleic acids, and
even cells, tissues and organisms. Aptamers exhibit significant advantages relative
to protein therapeutics in terms of size, synthetic accessibility and modification by
medicinal chemistry. During murine skeletal development, Notch-1 is strongly
localized within the condensing mesenchyme during the early stages of chondro-
genesis [1]. Notch signaling is implicated in the repression of chondrogenic differ-
entiation of mesenchymal stem cell (MSC) [2]. The purpose of this study was to
investigate the possibility of Notch1-antagonistic aptamer as nucleic acid thera-
peutics to induce chondrogenic differentiation of human bone marrow stromal
cells (hBMSCs).
Methods: 1) Cytotoxicity test. hBMSCs (1104 cells/well on 96 well plate) were
treated with three Notch1 aptamer clone candidates from 1 to 1000 nM for 7
days. On day 1, 4 and 7, MTT assay was performed. 2) Validation of Notch1-antag-
onistic aptamer to select Notch1-antagonistic aptamer, expression of Notch1
downstream target genes including Hes and Hey were investigated by RT-qPCR
on hBMSCs treated with each of Notch1 aptamer candidate in DMEM/F12. 3) Median
effective dose (ED50). Pellets of hBMSCs (2.5105 cells, passage 3e5) were
cultured in DMEM/F-12 supplemented with dexamethasone (10e7 M), BSA (7.5%
w/v), L-proline (50 mM), ascorbate-2-phosphate (50 mM), sodium pyruvate (1 mM)
and ITS (1% v/v) containing different concentration of Notch1 aptamer (1, 10,
100 and 1000 nM). 4) In vitro chondrogenic differentiation. The hBMSCs
(2.5105 cells, passage 3e5) were made by pellets and were cultured in chondro-
genic medium containing Notch1-antagoistic aptamer (200 nM) from day 0 to 14. 5)
Gene expression profiling with oligonucleotide microarrays. Expression profiling
was performed by Illumina Expression Beadchip Analysis Service using Illumina
HumanHT-12 v4 Expression BeadChip (Illumina, Inc., San Diego, CA, USA). Hierar-
chical clustering was performed complete linkage algorithm using GeneSpring GX
7.3.1 software (Agilent, Santa Clara, CA, USA).
Results: 1) Cytotoxicity test. The MTT data after exposure to the Notch1-antago-
nistic aptamer candidates from 1 to 1000 nM for 7 days showed no significant cyto-
toxicity. 2) Validation of Notch1-antagonistic aptamer. The gene expression of hes1
and hey1 significantly decreased in hBMSCs treated with Notch1-antagonistic
aptamer candidates for 7 days compared to those of untreated hBMSCs. 3) Median
effective dose. The gene expression of COL2, SOX9 and ACAN significantly
increased in hBMSCs treated with Notch1-antagonistic aptamer (100nM) for 14
days compared to those of untreated hBMSCs. 4) In vitro chondrogenic
